Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01501591
Other study ID # RAC 2111001
Secondary ID
Status Completed
Phase N/A
First received December 25, 2011
Last updated March 1, 2017
Start date November 2012
Est. completion date October 2015

Study information

Verified date February 2016
Source King Faisal Specialist Hospital & Research Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The total effect of a medication is the sum of its drug effect, placebo effect (meaning response of placebo), and their possible interaction. Current interpretation of the results of clinical trials (the gold standard in evidence based medicine) assumes no such interaction. Using a novel cross-over balanced placebo design and caffeine as a model drug, the investigators have recently shown that a negative interaction does exist; suggesting that the size of drug effect as currently measured by clinical trials may not be accurate. Due to the novelty of the findings and their important clinical practice and research implications, they need to be confirmed using another drug; and the size of drug effect measured using the novel design need to be directly compared to that measured using conventional clinical trial design. The results of the study are expected to further our understanding of a widely used medical intervention, i.e., placebo, and help assess the appropriateness of randomized clinical trials in determining the size of drug effect.


Description:

BACKGROUND:

The total effect of a medication is the sum of its drug effect, placebo effect (meaning response of placebo), and their possible interaction. Current interpretation of the results of clinical trials (the gold standard in evidence based medicine) assumes no such interaction. Using a novel cross-over balanced placebo design and caffeine as a model drug we have recently shown that a negative interaction does exist; suggesting that the size of drug effect as currently measured by clinical trials may not be accurate. Due to the novelty of the findings and their important clinical practice and research implications, they need to be confirmed using another drug; and the size of drug effect measured using the novel design need to be directly compared to that measured using conventional clinical trial design.

DESIGN:

A cross-over balanced placebo plus randomized placebo-controlled clinical trial design.

METHODS:

480 adults will be double-blindly randomized to three groups: first generation H-1 receptor antagonist- hydroxyzine (25 mg), placebo, or hydroxyzine+placebo group. The first two groups will receive the assigned intervention described by the investigators as hydroxyzine or placebo, in a randomized crossover design. The third group will receive hydroxyzine and placebo in a randomized double-blind placebo-controled crossover design. Group assignment will be concealed from volunteers and recruiters. Data collectors will be blinded to group assignment and intervention assignment. Volunteers will be partially deceived to the intervention assignment in the first two groups and blinded in the third group. The interventions to the third group will be also administered blindly. Serum hydroxyzine levels will be determined 3 hours post intervention from all volunteers to verify compliance and help maintain deception/blinding. The results of the study are expected to further our understanding of a widely used medical intervention, i.e., placebo, and help assess the appropriateness of randomized clinical trials in determining the size of drug effect.


Recruitment information / eligibility

Status Completed
Enrollment 480
Est. completion date October 2015
Est. primary completion date October 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Age of 18 to 50 years;

- Being healthy,

- Able to abstain from smoking and alcohol

- Medication-free for one week

- Able to reproducibly express oneself using a 100 mm visual analog scale (VAS).

Exclusion Criteria:

- clinically relevant deviation from normal health

- pregnancy or lactation

- hypersensitivity to hydroxyzine or related compounds

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Hydroxizine
25 mg orally, one time on two different days, 72 hours apart
Other:
Placebo
Matching placebo once on two different days, 72 hours apart.
Drug:
hydroxyzine/placebo
25 mg hydroxyzine or placebo once on two different days, 72 hours apart

Locations

Country Name City State
Saudi Arabia King Faisal Specialist Hospital & research Center Riyadh

Sponsors (1)

Lead Sponsor Collaborator
King Faisal Specialist Hospital & Research Center

Country where clinical trial is conducted

Saudi Arabia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area-under-the-curve for drowsiness Seven-hour-area-under-the-curve of drowsiness on 100 mm visual analog scales will be determined seven hours
Primary Area-under-the-curve for dryness of the mouth Seven-hour-area-under-the-curve of dryness of the mouth on 100 mm visual analog scales will be determined seven hours
Secondary Mean percent of time of reporting drowsiness on a dichotomous scale. Mean percent of time of reporting drowsiness on a dichotomous scale will also be determined. seven hours
Secondary Mean percent of time of reporting dryness of mouth Mean percent of time of reporting dryness of mouth on a dichotomous scale will also be determined. seven hours
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04650841 - The Role of the Opioid System in Placebo Effects on Pain and Social Rejection Early Phase 1
Completed NCT03694886 - The Effect of Tablet Size on Cognitive Performance Caffeine Phase 4
Not yet recruiting NCT04646460 - Context Interventions: Social Modeling and Initial Treatment Experience N/A
Completed NCT04571827 - The Influence of Expectations on Post-needling Soreness and Pain Processing After Dry Needling Treatment N/A
Completed NCT02802241 - Effects of Open-label vs Double-blind Treatment in IBS N/A
Not yet recruiting NCT06423365 - A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication. N/A
Completed NCT03017534 - Non-Specific Effects of Manual Therapy N/A
Completed NCT02578420 - Back to Basics - Effects, Narratives and Routes of Administration of Open-label Placebo N/A
Completed NCT02578212 - Trust Game and Placebo Response N/A
Completed NCT00426010 - Measuring Placebo Effect by Elimination and Investigating Mechanism of Action N/A
Completed NCT02365220 - Smartphone Application, Mood and Stress N/A
Completed NCT01501747 - The Placebo Effect May Involve Modulating Drug Bioavailability N/A
Recruiting NCT04766580 - Attention and Pain in Children With and Without Attention Deficit and/or Hyperactivity Disorder N/A
Completed NCT05004467 - Clinical Predictive Effects of Mulligan Treatment in Patients With Chronic Neck Pain N/A
Recruiting NCT03950999 - Experimental Pain Reporting Accuracy and Placebo Response N/A